{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:32:15Z","timestamp":1788049935862,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11883-006-0011-2","type":"journal-article","created":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T10:53:49Z","timestamp":1187520829000},"page":"324-329","source":"Crossref","is-referenced-by-count":24,"title":["Hypercoagulable states and strokes"],"prefix":"10.1007","volume":"8","author":[{"given":"Nean","family":"Matijevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/10408360590951171","volume":"42","author":"KK Wu","year":"2005","unstructured":"Wu KK, Matijevic-Aleksic N: Molecular aspects of thrombosis and antithrombotic drugs. Crit Rev Clin Lab Sci 2005, 42:249\u2013277.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev.med.47.1.315","volume":"47","author":"KK Wu","year":"1996","unstructured":"Wu KK, Thiagarajan P: Endothelial cell function in hemostasis and thrombosis. Ann Rev Med 1996, 47:315\u2013331.","journal-title":"Ann Rev Med"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1172\/JCI112225","volume":"76","author":"H Ishii","year":"1985","unstructured":"Ishii H, Majerus PW: Thrombomodulin is present in human plasma and urine. J Clin Invest 1985, 76:2178\u20132181.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"11_CR4","first-page":"73","volume":"32","author":"KK Wu","year":"2000","unstructured":"Wu KK, Matijevic-Aleksic N: Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Ann Med 2000, 32(Suppl 1):73\u201377.","journal-title":"Ann Med"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(98)09057-6","volume":"353","author":"V Salomaa","year":"1999","unstructured":"Salomaa V, Matei C, Aleksic N, et al.: Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999, 353:1729\u20131734.","journal-title":"Lancet"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1161\/01.STR.0000133340.37712.9b","volume":"35","author":"JM Olivot","year":"2004","unstructured":"Olivot JM, Labreuche J, Aiach M, Amarenco P: Soluble thrombomodulin and brain infarction. Case-control and prospective study. Stroke 2004, 35:1946\u20131951.","journal-title":"Stroke"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1468-1331.2004.00776.x","volume":"11","author":"E Nomura","year":"2004","unstructured":"Nomura E, Kohriyama T, Kozuka K, et al.: Significance of serum soluble thrombomodulin level in acute cerebral infarction. Eur J Neurol 2004, 11:329\u2013334.","journal-title":"Eur J Neurol"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0021-9150(00)00729-2","volume":"157","author":"V Salomaa","year":"2001","unstructured":"Salomaa V, Matei C, Aleksic N, et al.: Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis 2001, 157:309\u2013314.","journal-title":"Atherosclerosis"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/01.CIR.0000064894.97094.4F","volume":"107","author":"KK Wu","year":"2003","unstructured":"Wu KK, Aleksic N, Ballantyne CM, et al.: Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation 2003, 107:1729\u20131732.","journal-title":"Circulation"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0038-1657559","volume":"78","author":"AK Ohlin","year":"1997","unstructured":"Ohlin AK, Norlund L, Marlar RA: Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997, 78:396\u2013400.","journal-title":"Thromb Haemost"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1161\/01.CIR.103.10.1386","volume":"103","author":"KK Wu","year":"2001","unstructured":"Wu KK, Aleksic N, Ahn C, et al.: Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation 2001, 103:1386\u20131389.","journal-title":"Circulation"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2377-4-21","volume":"4","author":"JW Cole","year":"2004","unstructured":"Cole JW, Roberts SC, Gallagher M, et al.: Thrombomodulin Ala455Val Polymorphism and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women Study. BMC Neurol 2004, 4:21.","journal-title":"BMC Neurol"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00062752-199809000-00004","volume":"5","author":"R Landolfi","year":"1998","unstructured":"Landolfi R: Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol 1998, 5:327\u2013331.","journal-title":"Curr Opin Hematol"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162\u20132168.","journal-title":"Blood"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0038-1647968","volume":"35","author":"KK Wu","year":"1976","unstructured":"Wu KK, Hoak JC: Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications. Thromb Haemost 1976, 35:702\u2013711.","journal-title":"Thromb Haemost"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1055\/s-0038-1646673","volume":"39","author":"JW Cate ten","year":"1978","unstructured":"ten Cate JW, Vos J, Oosterhius H, et al.: Spontaneous platelet aggregation in cerebrovascular disease. Thromb Haemost 1978, 39:223\u2013229.","journal-title":"Thromb Haemost"},{"key":"11_CR17","first-page":"924","volume":"2","author":"KK Wu","year":"1974","unstructured":"Wu KK, Hoak JC: A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974, 2:924\u2013926.","journal-title":"Lancet"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jocn.2004.06.013","volume":"12","author":"T Tombul","year":"2005","unstructured":"Tombul T, Atbas C, Anlar O: Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J Clin Neurosci 2005, 12:429\u2013434.","journal-title":"J Clin Neurosci"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.STR.28.8.1557","volume":"28","author":"F Kooten van","year":"1997","unstructured":"van Kooten F, Ciabattoni G, Patrono C, et al.: Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 1997, 28:1557\u20131563.","journal-title":"Stroke"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1055\/s-0038-1649935","volume":"74","author":"K Konstantopoulos","year":"1995","unstructured":"Konstantopoulos K, Grotta JC, Sills C, et al.: Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 1995, 74:1329\u20131334.","journal-title":"Thromb Haemost"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.STR.26.1.52","volume":"26","author":"T Iwamoto","year":"1995","unstructured":"Iwamoto T, Kubo H, Takasaki M: Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger\u2019s disease. Stroke 1995, 26:52\u201356.","journal-title":"Stroke"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(97)80010-4","volume":"349","author":"PM Ridker","year":"1997","unstructured":"Ridker PM, Hennekens CH, Schmitz C, et al.: PIA1\/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997, 349:385\u2013388.","journal-title":"Lancet"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/01.STR.28.7.1392","volume":"28","author":"LE Carlsson","year":"1997","unstructured":"Carlsson LE, Greinacher A, Spitzer C, et al.: Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb\/IIIa), von Willebrand factor (GPIb\/IX), and collagen (GPIa\/IIa) are not correlated with an increased risk for stroke. Stroke 1997, 28:1392\u20131395.","journal-title":"Stroke"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1161\/CIRCULATIONAHA.105.557132","volume":"112","author":"A Smith","year":"2005","unstructured":"Smith A, Patterson C, Yarnell J, et al.: Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005, 112:3080\u20133087.","journal-title":"Circulation"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/01.STR.0000169924.60783.d4","volume":"36","author":"HS Markus","year":"2005","unstructured":"Markus HS, Hunt B, Palmer K, et al.: Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005, 36:1410\u20131414.","journal-title":"Stroke"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1161\/01.ATV.17.11.3321","volume":"17","author":"FB Smith","year":"1997","unstructured":"Smith FB, Lee AJ, Fowkes FG, et al.: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997, 17:3321\u20133325.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.100.7.736","volume":"100","author":"AR Folsom","year":"1999","unstructured":"Folsom AR, Rosamond WD, Shahar E, et al.: Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999, 100:736\u2013742.","journal-title":"Circulation"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/01.ATV.15.9.1269","volume":"15","author":"RP Tracy","year":"1995","unstructured":"Tracy RP, Bovill EG, Yanez D, et al.: Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1995, 15:1269\u20131279.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000054767","volume":"20","author":"MW Knuiman","year":"2001","unstructured":"Knuiman MW, Folsom AR, Chambless LE, et al.: Association of hemostatic variables with MRI-detected cerebral abnormalities: The Atherosclerosis Risk in Communities Study. Neuroepidemiology 2001, 20:96\u2013104.","journal-title":"Neuroepidemiology"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.ATV.19.6.1368","volume":"19","author":"G Maresca","year":"1999","unstructured":"Maresca G, Di Blasio A, Marchioli R, et al.: Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999, 19:1368\u20131377.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR31","first-page":"1799","volume":"294","author":"J Danesh","year":"2005","unstructured":"Danesh J, Lewington S, Thompson SG, et al.: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799\u20131809.","journal-title":"JAMA"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1161\/01.ATV.19.7.1751","volume":"19","author":"M Margaglione","year":"1999","unstructured":"Margaglione M, D\u2019Andrea G, Giuliani N, et al.: Inherited prothrombotic conditions and premature ischemic stroke. Sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol 1999, 19:1751\u20131756.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM199504063321403","volume":"332","author":"PM Ridker","year":"1995","unstructured":"Ridker PM, Hennekens CH, Lindpaintner K, et al.: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995, 332:912\u2013917.","journal-title":"N Engl J Med"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1055\/s-0037-1615092","volume":"79","author":"M Cushman","year":"1998","unstructured":"Cushman M, Rosendaal FR, Psaty BM, et al.: Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998, 79:912\u2013915.","journal-title":"Thromb Haemost"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1616195","volume":"86","author":"GJ Broze Jr","year":"2001","unstructured":"Broze GJ Jr: Protein Z-dependent regulation of coagulation. Thromb Haemost 2001, 86:8\u201313.","journal-title":"Thromb Haemost"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(00)04218-5","volume":"357","author":"M Vasse","year":"2001","unstructured":"Vasse M, Guegan-Massardier E, Borg JY, et al.: Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 2001, 357:933\u2013934.","journal-title":"Lancet"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1055\/s-0037-1613250","volume":"88","author":"S Lopaciuk","year":"2002","unstructured":"Lopaciuk S, Bykowska K, Kwiecinski H, et al.: Protein Z in young survivors of ischemic stroke. Thromb Haemost 2002, 88:536.","journal-title":"Thromb Haemost"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","volume":"88","author":"SR Poort","year":"1996","unstructured":"Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698\u20133703.","journal-title":"Blood"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.99.8.999","volume":"99","author":"PM Ridker","year":"1999","unstructured":"Ridker PM, Hennekens CH, Miletich JP: G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999, 99:999\u20131004.","journal-title":"Circulation"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0037-1613057","volume":"87","author":"AM Smiles","year":"2002","unstructured":"Smiles AM, Jenny NS, Tang Z, et al.: No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost 2002, 87:614\u2013621.","journal-title":"Thromb Haemost"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1161\/01.ATV.20.12.2511","volume":"20","author":"L Bajzar","year":"2000","unstructured":"Bajzar L: Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000, 20:2511\u20132518.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1161\/01.STR.0000088642.07691.15","volume":"34","author":"A Santamaria","year":"2003","unstructured":"Santamaria A, Oliver A, Borrell M, et al.: Risk of ischemic stroke associated with functional thromb-inactivatable fibrinolysis inhibitor plasma levels. Stroke 2003, 34:2387\u20132391.","journal-title":"Stroke"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1160\/TH04-09-0560","volume":"93","author":"ML Goor van","year":"2005","unstructured":"van Goor ML, Garcia EG, Leebeek F, et al.: The plasminogen activator inhibitor (PAI-1) 4G\/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost 2005, 93:92\u201396.","journal-title":"Thromb Haemost"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000047656","volume":"11","author":"CO Bang","year":"2001","unstructured":"Bang CO, Park HK, Ahn MY, et al.: 4G\/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion\/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001, 11:294\u2013299.","journal-title":"Cerebrovasc Dis"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/01.STR.0000174485.10277.24","volume":"36","author":"PG Wiklund","year":"2005","unstructured":"Wiklund PG, Nilsson L, Ardnor SN, et al.: Plasminogen activator inhibitor-1 4G\/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005, 36:1661\u20131665.","journal-title":"Stroke"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1055\/s-0038-1656042","volume":"77","author":"AJ Catto","year":"1997","unstructured":"Catto AJ, Carter AM, Stickland M, et al.: Plasminogen activator inhibitor-1 (PAI-1) 4G\/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997, 77:730\u2013734.","journal-title":"Thromb Haemost"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1657580","volume":"78","author":"GH Boers","year":"1997","unstructured":"Boers GH: Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997, 78:520\u2013522.","journal-title":"Thromb Haemost"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jama.1995.03530130055028","volume":"274","author":"CJ Boushey","year":"1995","unstructured":"Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049\u20131057.","journal-title":"JAMA"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00041327-200303000-00012","volume":"23","author":"ML Moster","year":"2003","unstructured":"Moster ML: Coagulopathies and arterial stroke. J Neuroophthalmol 2003, 23:63\u201371.","journal-title":"J Neuroophthalmol"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"997","DOI":"10.7326\/0003-4819-117-12-997","volume":"117","author":"KS Ginsburg","year":"1992","unstructured":"Ginsburg KS, Liang MH, Newcomer L, et al.: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117:997\u20131002.","journal-title":"Ann Intern Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-006-0011-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-006-0011-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-006-0011-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T00:13:08Z","timestamp":1587859988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-006-0011-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11883-006-0011-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}